PTJA14 – Pretomanid FGK is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).
The final project plan of the relative effectiveness assessment of ‘Pretomanid FGK is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB)’ is
OTCA24 revised final project plan now available
The revised final project plan and related documents from external experts for the Other Technologies Collaborative Assessment OTCA24 “The 24-hour blood pressure measurement device Mobil-O-Graph® with the built-in pulse wave velocity algorithm ARCSolver® to measure arterial stiffness for the optimization
EUnetHTA 2020 Assembly – Welcome Guide now available
The annual EUnetHTA Assembly aims to provide an overview into the year's activity, while stimulating discussion on HTA-related topics and looking to the network's next steps and future developments. Due to current events, we will be holding the 1st April
EUnetHTA Response to COVID-19
We all are faced with an unprecedented situation, a reminder of how fragile we as individuals are, how fragile our societies remain. EUnetHTA is a network of specialists, dedicated in their own jurisdictions to excellence and the support of their
PTJA09 – Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD)
This is the pharmaceutical Joint Assessment PTJA09 on brolucizumab. In February 2020, the European Commission granted marketing authorisation for Beovu® (brolucizumab) for the treatment of adults with neovascular (wet) AMD. This Joint Assessment aims to compare the clinical effectiveness and
EUnetHTA releases a new guidance document that supports health technology assessments: “Practical considerations when critically assessing economic evaluations”
The aim of this guidance document is to pass on some knowledge and know-how to all stakeholders with an interest in economic evaluations by providing an overview of important points for consideration when performing/assessing such evaluations, supported by a selection
Statement from the EUnetHTA Secretariat on COVID-19
Due to the developing COVID-19 scenario affecting Europe and with regard to the policy responses emerging on a per national basis from certain areas, the EUnetHTA Secretariat is implementing precautionary changes to its planned 2020 events schedule. This is following
PTJA11 – Cefiderocol for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options – project plan now available
The final project plan of the relative effectiveness assessment of ‘cefiderocol for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options’ is now available for access. The final assessment report will be published
PTJA08 – Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity
This is the pharmaceutical Joint Assessment PTJA08 – on siponimod for the treatment of active SPMS. In January 2020, the European Commission granted marketing authorisation for Mayzent® (siponimod) for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS)
PTJA06 – Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant
This is the pharmaceutical Joint Assessment PTJA06 – on polatuzumab vedotin for the treatment of relapsed/refractory DLBCL. In January 2020, The European Commission granted conditional marketing authorisation for Polivy® (polatuzumab vedotin), in combination with bendamustine plus MabThera® (rituximab) (BR), for